MOTS-c
Mitochondrial-derived peptide
The Ground Truth Score
four plain questions, never one numberStriking in mice, barely tested
Bottom line
One of the most exciting longevity peptides in animal research, and one of the least tested in humans, where the very first clinical trial only began in 2026.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
Advisory: yesRecommended, not legal yetAn FDA advisory committee recommended this for the 503A Bulks List in July 2026. Read that precisely: it is a recommendation, not a rule. Nothing changed about what is legal, FDA still has to run notice-and-comment rulemaking, and it can decline. As of October 12, 2026 it is still bought the same gray-market way it was before the vote.
Recommended for the 503A Bulks List by FDA's Pharmacy Compounding Advisory Committee, 7-5 with two abstentions, on July 23 2026. FDA's own briefing document recommended against adding it, citing no human safety data and concern about immune reactions to an injected peptide. The vote is advisory and binds nothing, and as of October 12 2026 FDA has published no proposed rule, so it is still not lawfully compoundable. FDA lists the nomination as withdrawn.
Legal status as of 2026-10-12. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported, not prescribed, and explicitly experimental.
Reported, not prescribed. Verify your vial and your math.
First documented human use
No human results exist. The first registered human trial, a randomized, placebo-controlled Phase 2a study of insulin sensitivity in 120 adults with prediabetes (NCT07505745), began in February 2026 and has not reported.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- Acts as an 'exercise mimetic,' improving metabolism and endurance.
- Improves insulin sensitivity and metabolic health.
- May slow aspects of aging at the cellular level.
The data behind each bullet
What actually backs it
Exercise mimetic / boosts endurance.
In aged (22-month) mice, MOTS-c markedly improved running/endurance capacity. No human performance data exists.
Reynolds et al., Nat Commun 2021, aged-mouse endurance ↗Improves insulin sensitivity.
Strong animal and mechanistic data on glucose metabolism; the first human trial testing exactly this began in 2026 with no results yet.
NCT07505745, Phase 2a MOTS-c in prediabetes. ClinicalTrials.gov ↗Slows cellular aging.
A 2025 mechanistic paper reported MOTS-c prevents pancreatic islet-cell senescence in a model. This is a laboratory mechanism, not a human outcome.
Kong et al., Exp Mol Med 2025, islet-cell senescence ↗No published case report or study documents hypersensitivity, flushing or histamine-type reactions with MOTS-c; online reports of immune-type reactions and fever are unconfirmed.
Absence of controlled data. FDA's adverse-event database had zero MOTS-c reports through March 2025, and FDA says it cannot conclude immunogenicity and aggregation risks with subcutaneous injection are absent. USADA lists user-reported reactions as anecdotes.
FDA briefing document, MOTS-c, July 2026 PCAC ↗MOTS-c is a cationic, amphipathic peptide with antibacterial and immune-modulating activity in mice and mouse cells.
Mouse peritonitis model and mouse monocyte differentiation. No human data.
Rice et al., eLife 2026, MOTS-c as a host defense peptide ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it, a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
The two honest objective proxies are a 14-day CGM (glucose mean/variability) and lab VO2max/CPET, both map to MOTS-c's claimed metabolic and endurance effects, but both are confounded by diet/training and unproven in humans.
Bloodwork
Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.
MOTS-c is a 16-aa mitochondrial-derived peptide that acts intracellularly through AMPK as an "exercise mimetic"; its own level is measurable only by a research ELISA (not any routine panel), and it produces no efficacy footprint on standard labs that could be separated from diet, training, or weight.
Read this before you spend on labs
Routine bloodwork cannot confirm that MOTS-c is working. There are no completed human efficacy trials of exogenous MOTS-c, and endogenous MOTS-c is quantifiable only by a research ELISA, not any LabCorp/Quest offering. Mechanistically it is a metabolic/AMPK peptide, so the only place anyone would even look is fasting insulin, HbA1c, and fasting glucose (with HOMA-IR), but those markers are dominated by diet, training load, and body weight, and no human data ties an injected MOTS-c dose to a shift in any of them. Any metabolic-panel improvement seen while running MOTS-c cannot be attributed to the peptide over the lifestyle changes that typically accompany it. Treat metabolic labs as general health context, not as proof MOTS-c is doing anything.
Other ways to track it
14-day continuous glucose monitor (Dexcom Stelo / Abbott Lingo), mean glucose, time-in-range, glucose variability (SD/CV), post-meal excursions
A working metabolic effect would show a modest drop in mean glucose, tighter variability (lower CV), and flatter post-meal excursions versus a matched baseline. No proven human magnitude exists (the first human trial only began in 2026), and any change is easily confounded by diet, carbs, sleep, and training, so hold meals and routine constant across baseline vs on-cycle windows or the signal is meaningless.
MOTS-c activates AMPK and increases skeletal-muscle glucose uptake and fatty-acid oxidation, improving insulin sensitivity in animal models; if that translates to humans it should surface as lower ambient glucose and tighter excursions on CGM.
Lab CPET (graded treadmill/cycle with gas exchange) for a true VO2max, or a consumer wearable estimate (Garmin/Apple Watch/COROS) as a rough trend line only
If the exercise-mimetic effect is real in humans, aerobic capacity / time-to-exhaustion should trend upward. But VO2max responds powerfully to training itself, and wearable estimates are noisy run-to-run, so a small change cannot be pinned on the peptide without a lab CPET and a held-constant training block. No human efficacy data exists yet, this is the weaker of the two proxies because attribution is dominated by the training confound.
In aged mice MOTS-c markedly improved running/endurance capacity as an exercise mimetic; the human-relevant footprint of that claim is cardiorespiratory fitness (VO2max), not any routine blood marker.
Bottom line
MOTS-c's first human trial only began in 2026, so there is zero completed human efficacy data, everything here is animal-derived plausibility (AMPK/insulin-sensitivity from cell and rodent work, endurance from aged-mouse studies). CGM and VO2max are the right objective proxies because they map to those two animal findings, but both readouts are dominated by diet, sleep, and training, and VO2max is especially confounded because training alone moves it. A change you observe is far more likely to come from lifestyle than from the peptide, so standardize every variable, use a true baseline, and treat any signal as suggestive, not proof. There is no validated human blood biomarker of MOTS-c efficacy, so blood adds nothing beyond a noisier version of the CGM signal.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data, bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed, with striking animal support: MOTS-c is a peptide encoded inside mitochondrial DNA that activates AMPK, a master metabolic switch, and antioxidant gene programs, behaving like an exercise mimetic. The first human trial only began in 2026.
Dosing & handling
What users and clinicians report
Reported, not prescribed, and explicitly experimental. Community and research protocols cite 5–10 mg subcutaneously, 3–5× per week. There is no established clinical dose.
The first human trial is still recruiting and has not disclosed its dose. Any dose is a guess informed by mouse studies.
Timing & food
Community and research protocols: 2–5× per week, often in the morning and fasted, on the rationale that it's an 'exercise-mimetic' tied to metabolism. The exact timing is unestablished.
Half-life
Not well characterized in humans; research and community protocols dose several times weekly. Its development was historically slowed by stability and delivery challenges.
Reconstitution sensitivity
Standard peptide fragility, refrigerate, don't shake. Stability has been a real formulation problem for this one, so handling care matters more than most.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Thin first-person corpus, most indexed MOTS-c content is vendor SEO and academic papers, not user logs.
Consistency
Only one lived claim converges (endurance / work capacity); metabolic and fat-loss claims are sparse, mixed, and stack-confounded.
Source credibility
If you only read the blogs you'd massively overrate it; the real ledger (MESO-Rx, including 'doing absolutely nothing' threads) is small.
- Reported uses center on metabolic health, endurance, and fat loss, usually by people already optimizing hard.
- Reports are enthusiastic but sparse, and very hard to separate from training and diet.
- Few side-effect reports; the honest read is 'not enough people have used it carefully to know.'
Placebo risk, Low
What people chase here, insulin sensitivity, endurance, fat loss, is objective and measurable, so placebo can't fake it. The catch is almost nobody is actually measuring.
Risk panel
What could go wrong
Adverse events
Unknown. FDA's July 2026 review found no human safety data and no adverse-event reports, and said it is concerned about immune reactions to an injected peptide. People who buy it online report palpitations, injection-site irritation, insomnia, fever and immune-type reactions. These are anecdotes: no case report or study has confirmed or explained them.
Theoretical concerns
As a naturally occurring signaling peptide, the theoretical profile is reassuring, but 'endogenous' does not mean 'safe at injected doses.'
Contraindications
Undefined, there is no human safety dataset to derive them from.
Honest unknowns
Effective dose, route, durability, how long it lasts in blood (FDA cites rapid breakdown in human blood in a lab study), immune reactions to the injected peptide, drug interactions, and essentially all human safety.
Confound watch
MOTS-c is popular with people already optimizing hard, training, GLP-1s, caloric control. Any metabolic improvement they report is hopelessly entangled with those much-better-evidenced variables.
History
Discovery → first use → status
Update: an FDA advisory panel voted in favor of this one on July 23-24, 2026
The FDA's Pharmacy Compounding Advisory Committee voted to recommend adding this to the 503A Bulks List, meaning compounding pharmacies could legally prepare it. The vote: 7-5, with two abstentions. Now read the fine print, because it matters more than the headline. The vote is advisory and changes nothing today: FDA still has to go through formal rulemaking, which can take a year, and it has overruled its own panels before. As of October 12, 2026, eleven weeks after the vote, FDA has not published a proposed rule, so this is still not lawfully compoundable. FDA's own scientists recommended AGAINST adding it, citing thin human evidence and unassessed immunogenicity risk, and the committee voted the other way. That committee is also not neutral: it was reconstituted with recent appointees, and several work at or run clinics that sell peptide treatments. And none of this is a finding that the compound works. A compounding-eligibility vote is not drug approval, and it is not evidence. Our grade here is unchanged, because the evidence did not change.
Vote tallies as reported by the press (STAT, McDermott Will and Schulte); FDA has not posted tallies, minutes or a transcript, and its meeting materials are on its meeting page. Rechecked October 12, 2026: no proposed rule in the Federal Register through October 8, and docket FDA-2025-N-6895 closed July 22, 2026. Nothing here is final, so check the current rule before acting.
FDA, PCAC meeting, July 23-24 2026 ↗- 2015MOTS-c identified as a peptide encoded within mitochondrial DNA.
- 2015–2025Animal and in-vitro work shows metabolic and endurance effects; development slowed by delivery and stability challenges.
- 2025Mechanistic paper links MOTS-c to delayed islet-cell senescence.
- Apr 2026First registered human trial (Phase 2a, placebo-controlled, prediabetes) posted, no results yet.
- Apr 22 2026Off FDA Category 2: FDA's page lists it as nominated but withdrawn by the nominators. Not a safety finding, not Category 1 and not an approval. PCAC review scheduled Jul 23 2026.
- Jul 23 2026PCAC voted 7-5 (2 abstentions) to recommend MOTS-c for addition to the 503A Bulks List. Advisory only: no FDA proposed rule as of Oct 12 2026, and no evidence grade moves on a compounding vote.
Verification
The COA standard, applied
Injected, so the full standard applies: HPLC ≥98%, mass-spec identity, LAL endotoxin, from an independent lab. Identity verification is especially important for an expensive peptide that is easy to under-fill or substitute.
The full verification standard →Sources
Where this comes from
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.